Reply to Bareille et al. Are Viscoelastometric Assays of Old Generation Ready for Disposal? Comment on "Volod et al. Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices. J. Clin. Med. 2022, 11 , 860"

[...]we mentioned this phenomenon that uniquely defines COVID-19 patients. [...]a recent review of the literature using the MeSH term COVID associated coagulopathy reveals that this term was a standard descriptor for the singular observation of these patients to develop early clots that required delicate and closely monitored anti-coagulation [8,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37]. [...]the “1.5 to 2.5 times control” UFH therapeutic range was established is instructive regarding the history of RCTs in offering guidance for heparin anticoagulation. [...]the guidelines and algorithms are still in a state of evolution [51].